-Record Net Product Sales of $544 Million in 2Q23, an Increase of 26% Over 2Q22, Contributing to Total Revenues of $604 Million in 2Q23-
-Strong PADCEV® Growth Driven By Combination First-Line.
-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million-
-PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for. | April 27, 2023